Microbubble contrast agent for color Doppler US: effect on breast masses. Work in progress.

Kedar, R P; Cosgrove, David O.; McCready, V. R.; Bamber, Jeffrey C.; Carter, E R

doi:10.1148/radiology.198.3.8628854

Cited by 177 publications

(115 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to our results, the sensitivity and the specificity of microvessel detection in living tissue is increased with HFCDUS using microbubble contrast agents that enhance the acoustic signal from blood vessels compared to HFCDUS without contrast agent. 13,30,36 Thus, we have demonstrated the threshold of intra-tumor vessel detection of 40 mm in diameter, as proposed by Burns. 37 New interest has developed in contrast-enhanced ultrasound techniques as the unenhanced Doppler ultrasound applied within tumors only depict large vessels (4100 mm) confined to superficial parts of the body.…”

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

Dynamic assessment of antiangiogenic therapy by monitoring both tumoral vascularization and tissue degeneration

et al. 2006

View full text Add to dashboard Cite

Tumor growth is dependent both on endothelial and tumor cells. The aim of this study was to investigate dynamically whether changes in tumor vasculature implicate tumor tissue degeneration during antiangiogenic therapies. In order to quantify intra-tumor vascularization and necrosis, we have used ultrasound technology. This study has identified essential parameters needed to quantify specifically and sensitively the number of microvessels and the extent of necrosis in xenografted human carcinomas during natural tumor evolution, using contrast-enhanced high-frequency ultrasonography with (HFCDUS) or without (HFUS) color Doppler. We showed that quantification of intra-tumor microvessels between HFCDUS and immunohistochemistry is correlated using an anti-CD31 antibody. Furthermore, quantification of tumor necrosis with HFUS was confirmed by histological examination of hematoxylin-eosin-saffraninstained sections over the observation period. Subsequently, for the assessment of novel angiogenic inhibitors, HFCDUS and HFUS were used to elucidate the underlying dynamics linking vessel inhibition and tumor eradication. We describe a novel application for HFCDUS/HFUS that constitutes an effective, convenient, and non-invasive method for clinical assessment of angiogenic inhibitors. In conclusion, we showed that tumor cells abruptly became necrotic following an antivascular therapy, whereas untreated tumors were protected from degeneration by a significant blood supply.

show abstract

Section: Discussionmentioning

confidence: 70%

“…Intra-tumor echogenicity was converted into percentage of necrosis using the standard curve obtained above, where y ¼ À8.1193x+154. 36.…”

Section: Assessment Of Intra-tumor Necrosis With Hfus After Antiangiomentioning

confidence: 99%

Dynamic assessment of antiangiogenic therapy by monitoring both tumoral vascularization and tissue degeneration

et al. 2006

View full text Add to dashboard Cite

show abstract

“…There are relatively few reports in the literature on contrast enhanced ultrasound evaluations of breast masses and most deal with qualitative image assessments and diagnostic accuracy only (e.g., Forsberg et al 2004;Hochmuth et al 2002;Kedar et al 1996;Kim et al 2002;Madjar et al 2000;Martinez et al 2003;Özdemir et al 2004;Stuhrmann et al 2000). Three studies on quantitative assessments of breast lesions using contrast enhanced Doppler imaging have been published (Huber et al 2001;Kettenbach et al 2005;Yang et al 2002).…”

Section: Discussionmentioning

confidence: 99%

Comparing Contrast-Enhanced Color Flow Imaging and Pathological Measures of Breast Lesion Vascularity

Forsberg

Kuruvilla

Pascua

et al. 2008

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

This study was conducted to compare quantifiable measures of vascularity obtained from contrastenhanced color flow images of breast lesions to pathologic vascularity measurements. Nineteen patients with solid breast masses received Levovist ® Injection (10 ml at 300 mg/ml; Berlex Laboratories, Montville, NJ, USA). Color flow images of the mass pre and post contrast were obtained using an HDI 3000 scanner (Philips Medical Systems, Bothell, WA, USA) optimized for clinical scanning on an individual basis. After surgical removal specimens were sectioned in the same planes as the ultrasound images and stained with an endothelial cell marker (CD31). Microvessel area (MVA) and intratumoral microvessel density (MVD) were determined for vessels 10-19μm, 20-29μm, 30-39μm, 40-49μm, and >50μm in diameter using a microscope and image processing software. From the ultrasound images the number of color pixels before and after contrast administration relative to the total area of the breast mass was calculated as a first order measure of fractional tumor vascularity. Vascularity measures were compared using reverse stepwise multiple linear regression analysis. In total, 58 pathology slides (with 8106 frames) and 185 ultrasound images were analyzed. There was a significant increase in flow visualization pre to post Levovist injection (p=0.001), but no differences were found between the 11 benign and the 8 malignant lesions (p>0.35). Ultrasound vascularity measurements post contrast correlated significantly with pathology (0.15≤r 2 ≤0.46; p<0.03). The 30-39μm vessel range contributed most significantly to the MVD relationship (p<0.001), while the MVA was mainly influenced by vessels 20-29μm (p<0.004). Pre contrast ultrasound only correlated with pathology for relative MVA (r 2 =0.16; p=0.01). In conclusion, contrast-enhanced color flow imaging provides a noninvasive measure of breast tumor neovascularity corresponding mainly to vessels 20-39μm in diameter, when used in a typical clinical setting.

show abstract

“…13,14 In addition, contrast agents may be able to differentiate between malignant and benign tumor vascularity. 15,16 The results of this study suggest that the contrast agent improved the sensitivity of the gray scale harmonic imaging for detection of small tumors (<1 cm). It is very important to detect all tumors for complete ablation therapy in the clinical setting.…”

mentioning

confidence: 71%

The role of contrast‐enhanced sonography for radiofrequency ablation of liver tumors.

Liu

Goldberg

Merton

et al. 2001

J of Ultrasound Medicine

View full text Add to dashboard Cite

Objective. To assess the feasibility and usefulness of contrast-enhanced sonography for tumor detection and guidance of liver VX2 tumor ablation and to evaluate post radiofrequency ablation effectiveness. Methods. VX2 tumors were implanted into the livers of 6 rabbits. Both conventional and harmonic gray scale and power Doppler imaging were performed with a commercially available scanner to evaluate the liver tumors before and after intravenous injection of a sonographic contrast agent before and after radiofrequency ablation. Contrast-enhanced imaging was used to detect the tumors before ablation, to guide needle insertion, and to measure the ablation sites after radiofrequency ablation. Pathologic examination was performed for comparison. Results. Three tumors were seen without contrast enhancement, whereas 10 tumors (<1 cm) were detected with contrast enhancement. Intentionally, 2 tumors were completely ablated and 5 tumors were partially ablated. In 3 cases, incompletely ablated tumors could only be identified on contrast-enhanced Doppler imaging by enhancing the detection of residual tumor vascularity. There was excellent concordance between sonographic imaging and gross pathologic findings. Conclusions. Contrast-enhanced sonographic imaging appears useful for detection of liver tumors and for guiding and monitoring tumor ablation therapies.

show abstract

Microbubble contrast agent for color Doppler US: effect on breast masses. Work in progress.

Abstract: Injection of a microbubble agent enabled accurate differentiation of benign masses from carcinomas.

Cited by 177 publications

References 0 publications

Dynamic assessment of antiangiogenic therapy by monitoring both tumoral vascularization and tissue degeneration

Dynamic assessment of antiangiogenic therapy by monitoring both tumoral vascularization and tissue degeneration

Comparing Contrast-Enhanced Color Flow Imaging and Pathological Measures of Breast Lesion Vascularity

The role of contrast‐enhanced sonography for radiofrequency ablation of liver tumors.

Contact Info

Product

Resources

About